Medical Oncologist
Targeted therapy for unknown primary
Cancer of Unknown Primary: — Can Molecular Testing Help?
When doctors cannot find where your cancer started, molecular testing of the tumour tissue can still identify specific mutations. Some of those mutations match treatments approved regardless of the primary site.
Medically reviewed by Dr. T. Raghavender Reddy, Medical Oncologist, MBBS · DM (Medical Oncology) · MD (Radiation Oncology) · Last reviewed August 2026
- No primary, not no options — Molecular testing looks for mutations, not the site of origin. Matched treatments exist for several mutations found in cancer of unknown primary.
- Testing changes treatment decisions — NCCN now recommends comprehensive genomic profiling as part of the standard workup for cancer of unknown primary.
- Tissue-agnostic approvals exist — Several drugs are approved based on the mutation alone, regardless of which organ the cancer came from.
- Results guide the full plan — Even when no actionable mutation is found, a tissue-of-origin test can help your team choose the most appropriate systemic therapy.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Molecular testing of your tumour tissue can identify specific mutations that match approved treatments, even when no primary site is found. NCCN guidelines recommend comprehensive genomic profiling for cancer of unknown primary because tissue-agnostic drug approvals now exist for mutations such as MSI-H, NTRK fusions, and BRAF V600E, regardless of where the cancer started.
How do doctors treat cancer when they cannot find where it started?
Cancer of unknown primary means that despite imaging, biopsy, and blood tests, the original site cannot be confirmed.
For many years, treatment was empirical: a broad chemotherapy regimen given without knowing the primary. That approach has changed. NCCN guidelines now recommend comprehensive genomic profiling for most patients with cancer of unknown primary.
The reason is straightforward. Several treatments are now approved based on a tumour's molecular characteristics alone, not its organ of origin. Finding one of those characteristics in your tumour can change what you are offered.
Which mutations does molecular testing look for in cancer of unknown primary?
- MSI-H or dMMR (mismatch repair deficiency)Qualifies your tumour for pembrolizumab regardless of primary site, under FDA and NCCN guidance.
- High tumour mutational burden (TMB-high)A separate basis for pembrolizumab consideration in any solid tumour, independent of MSI status.
- NTRK gene fusionsLarotrectinib and entrectinib are approved for any solid tumour with this fusion — a clear tissue-agnostic example.
- BRAF V600E mutationDabrafenib combined with trametinib is approved for any solid tumour carrying this specific change.
- RET gene fusionsSelpercatinib has received approval for RET fusion-positive solid tumours regardless of where the cancer originated.
- HER2 amplification or overexpressionHER2-targeted therapies apply in several cancer types; finding amplification opens a conversation about these agents.
- BRCA1 or BRCA2 mutationsPARP inhibitors may be worth discussing, particularly if the tumour resembles a breast or ovarian primary.
- PD-L1 expressionAssessed alongside MSI-H and TMB to help your oncologist decide whether immunotherapy is likely to be useful for you.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Get a straight answer from a specialist
45 minutes, your reports reviewed, your questions answered in plain language.
What happens during molecular testing for cancer of unknown primary?
Existing biopsy tissue is retrieved
Your pathologist retrieves the sample already taken. A new biopsy is only needed if the original sample is too small or too degraded to sequence.
Comprehensive genomic profiling is requested
Next-generation sequencing screens for mutations across a large panel of genes simultaneously. This gives a fuller picture than single-gene tests.
A tissue-of-origin test may run at the same time
RNA-based profiling can indicate which organ the cancer most closely resembles, even when imaging cannot confirm it. It does not always give a definitive answer, but it can narrow the field.
Results are reviewed by a multidisciplinary team
Your oncologist, pathologist, and sometimes a molecular tumour board consider what was found and which treatments correspond to those findings.
Treatment is matched to results
Actionable mutations are matched to approved drugs or relevant clinical trials. If no actionable mutation is found, your team recommends the best available systemic therapy based on the full picture.
What if the molecular test finds nothing actionable?
Not every tumour carries a mutation that matches an approved drug. That is a real possibility, and your oncologist should be able to tell you plainly what was and was not found.
When nothing actionable is identified, treatment usually follows the tissue-of-origin result if one was obtained, or a platinum-based regimen if the tissue type suggests it. NCCN guidance also recommends considering clinical trials, which may be open specifically for cancer of unknown primary patients.
Ask your team what the tissue-of-origin result showed, even if nothing actionable was found. Knowing that the tumour most closely resembles a lung or gastrointestinal primary still helps your oncologist choose the most appropriate regimen.
Explore 119 more Targeted Therapy Basics, Testing & Your Cancer Type topics
Cancer-Type Specific Targeted Therapy
- CML Treatment with TKIs: Living a Normal Life Span
- Cancer of Unknown Primary: Can Molecular Testing Help?
- GIST Treatment: Why This Cancer Changed Targeted Therapy Forever
- Targeted Therapy for Bile Duct Cancer (Cholangiocarcinoma)
- Targeted Therapy for Bladder and Urothelial Cancer
- Targeted Therapy for Brain Tumours and Glioma
- Targeted Therapy for Breast Cancer: HER2, HR+ and Triple Negative
- Targeted Therapy for CLL and Lymphoma
- Targeted Therapy for Cervical and Endometrial Cancer
- Targeted Therapy for Childhood Cancers
- Targeted Therapy for Colorectal Cancer: RAS, BRAF and HER2
- Targeted Therapy for Head and Neck Cancer
- Targeted Therapy for Kidney Cancer (RCC)
- Targeted Therapy for Liver Cancer (HCC)
- Targeted Therapy for Lung Cancer: Every Mutation and Drug Explained
- Targeted Therapy for Melanoma: BRAF and MEK Inhibitors
- Targeted Therapy for Multiple Myeloma
- Targeted Therapy for Neuroendocrine Tumours
- Targeted Therapy for Ovarian Cancer: PARP Inhibitors and Beyond
- Targeted Therapy for Pancreatic Cancer: Limited but Real Options
- Targeted Therapy for Prostate Cancer
- Targeted Therapy for Sarcoma
- Targeted Therapy for Stomach and Gastroesophageal Cancer
- Targeted Therapy for Thyroid Cancer
- Targeted Therapy in AML: Beyond Standard Chemotherapy
- Tumour-Agnostic Drugs: When the Mutation Matters More Than the Organ
Before You Start - Preparation & Baseline
- 25 Questions to Ask Your Oncologist Before Starting Targeted Therapy
- Before You Start Targeted Therapy: The Complete Preparation Checklist
- Dental Check-Up Before Cancer Treatment: Why It Matters
- Financial Planning Before Starting Long-Term Targeted Therapy
- How Long After Surgery Can You Start Targeted Therapy?
- How to Store Your Targeted Therapy Tablets Correctly
- Setting Up a Dosing Routine You Won't Forget
- Should Targeted Therapy Be Taken With Food or on an Empty Stomach?
- Vaccinations Before and During Cancer Treatment
- What to Expect in Your First Month on Targeted Therapy
- Which Baseline Tests Are Done Before Starting a TKI?
- Which of Your Existing Medicines Must Stop Before Targeted Therapy
- Why You Need an ECHO and ECG Before Certain Cancer Drugs
Biomarker & Molecular Testing
- Can Mutation Testing Be Done on an Old Biopsy Block or Slides?
- Cost of NGS and Mutation Testing in India: 2026 Price Guide
- Do I Need Genetic Testing Before Starting Targeted Therapy?
- Germline vs Somatic Testing: The Difference Nobody Explains Properly
- Getting a Second Opinion on Your Genomic Report
- How Long Do Mutation Test Results Take in India? Realistic Timelines
- How to Read Your Molecular Pathology Report, Line by Line
- IHC, FISH, PCR or NGS: Which Mutation Test Is Right for Your Cancer?
- Is Mutation Testing Worth It If I Can't Afford the Drug?
- Liquid Biopsy vs Tissue Biopsy: Which Test Do You Need?
- My Report Says a Mutation Is 'Actionable': What Does That Mean?
- No Mutation Found in My Report: What Are My Options Now?
- Should I Start Chemotherapy While Waiting for Mutation Results?
- Should You Repeat Molecular Testing After Your Cancer Progresses?
- Single-Gene Test or Full Panel? How to Choose Without Wasting Money
- What Are PD-L1, TMB and MSI, and Do They Affect Targeted Therapy?
- What Does 'Variant of Uncertain Significance' (VUS) Mean?
- What Happens If There Isn't Enough Tissue for Mutation Testing?
- What Is NGS (Next-Generation Sequencing) Testing in Cancer?
- What Is a Molecular Tumour Board and Why Should You Want One?
- Which Cancers Should Always Be Tested for Mutations? A Checklist
- ctDNA and MRD Testing: Tracking Cancer Through a Blood Test
Foundations & How Targeted Therapy Works
- Adjuvant and Neoadjuvant Targeted Therapy: Treatment Before or After Surgery
- Antibody-Drug Conjugates (ADCs): The Smart Bombs of Cancer Treatment
- Biosimilars and Generic Targeted Therapy Drugs: What They Are
- Can Targeted Therapy Be Combined with Chemotherapy or Radiation?
- Can Targeted Therapy Cure Cancer? An Honest Answer
- First-Line, Second-Line and Beyond: How Treatment Lines Work
- How Doctors Decide Between Chemo, Immunotherapy and Targeted Therapy
- How Does Targeted Therapy Actually Work? Explained Without Jargon
- How Long Does Targeted Therapy Take to Start Working?
- Is Targeted Therapy Painful? What the Treatment Actually Feels Like
- Is Targeted Therapy a Type of Chemotherapy? Clearing Up the Confusion
- Oral Tablets vs IV Infusion Targeted Therapy: What's the Difference?
- Precision Oncology vs Personalised Medicine: Are They the Same Thing?
- Targeted Therapy Success Rates: What the Numbers Really Mean
- Targeted Therapy for Stage 4 Cancer: What You Can Realistically Expect
- Targeted Therapy vs Chemotherapy: 12 Differences That Actually Matter
- Targeted Therapy vs Immunotherapy: Which One Is Right for You?
- The 8 Main Types of Targeted Therapy Drugs (With Examples)
- What Do Cancer Drug Endings Like -nib, -mab and -tinib Mean?
- What Is Targeted Therapy for Cancer? A Complete Patient Guide
- Which Cancers Can Be Treated with Targeted Therapy? Full List
- Why Didn't My Doctor Recommend Targeted Therapy for Me?
Mutation & Target-Specific Pages
- ALK-Positive Lung Cancer: Drugs, Response and What Comes Next
- Antiangiogenic Drugs (VEGF Inhibitors): How Starving a Tumour Works
- BCR-ABL and the Philadelphia Chromosome in CML
- BRAF V600E Mutation: Targeted Therapy Across Multiple Cancers
- BRCA vs HRD Testing: Which One Determines PARP Inhibitor Eligibility?
- BRCA1 and BRCA2 Mutations in Cancer Treatment: PARP Inhibitors
- BTK Inhibitors in CLL and Lymphoma
- CD20, CD38 and Other Antibody Targets in Blood Cancers
- CDK4/6 Inhibitors in Hormone-Positive Breast Cancer
- Co-Mutations: When You Have Two Mutations at Once
- EGFR Exon 20 Insertion: Why It's Different and Harder to Treat
- EGFR Mutation in Lung Cancer: Complete Patient Guide
- ESR1 Mutation: Why Your Hormone Therapy Stopped Working
- FGFR Alterations in Bladder and Bile Duct Cancer
- FLT3 Mutation in AML: What It Means for Your Prognosis
- HER2 Mutation in Lung and Gastric Cancer
- HER2-Low Breast Cancer: A New Category That Changes Treatment
- HER2-Positive Breast Cancer: The Full Targeted Therapy Roadmap
- IDH1 and IDH2 Mutations in Glioma, AML and Bile Duct Cancer
- KIT and PDGFRA Mutations in GIST
- KRAS G12C Mutation: The Target That Was Undruggable for 40 Years
- KRAS Mutation but Not G12C: What Are My Options?
- MET Exon 14 Skipping and MET Amplification Explained
- MSI-High and Mismatch Repair Deficiency: Testing and Treatment
- NRG1, MET, RET and Other Rare Fusions: Where to Get Tested
- NTRK Fusion: One Drug for Many Different Cancers
- Osimertinib: What to Expect, Side Effects and How Long It Works
- PALB2, ATM and Other BRCA-Like Genes: Do They Get the Same Drugs?
- PIK3CA Mutation in Breast Cancer: Alpelisib and What to Expect
- PSMA and AR-Targeted Therapy in Prostate Cancer
- RET Fusion Cancer: Lung, Thyroid and Beyond
- ROS1-Positive Cancer: A Rare Mutation with Excellent Options
- TP53 Mutation: Why There's Still No Targeted Drug for It
- Understanding Variant Allele Frequency (VAF) in Your Report
- What If My Mutation Has No Approved Drug Yet?
- mTOR Inhibitors in Cancer: Everolimus and Temsirolimus
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
Do I need a new biopsy to have molecular testing done?
Usually not. Most molecular profiling is done on the tissue sample already taken during your original biopsy. A new biopsy is requested when the original sample is too small, too degraded, or was taken too long ago for reliable sequencing. Ask your oncologist whether the sample already in storage is sufficient before agreeing to a new procedure.
How long does molecular profiling take?
Turnaround varies between laboratories and depends on whether the sample needs to travel to a specialist centre. Your oncologist can give you the expected timeframe for the specific laboratory being used. If treatment is urgent, your team will usually start the most appropriate available therapy while results are awaited rather than delaying everything.
What does tissue-agnostic approval mean and why does it matter for cancer of unknown primary?
A tissue-agnostic approval means a drug is approved for any solid tumour carrying a specific mutation or marker, regardless of where the cancer started. For patients with cancer of unknown primary, this matters more than for most, because it removes the need to identify the primary site before a targeted treatment can be considered. The mutation in your tumour is what qualifies you, not the organ label.
Is comprehensive genomic profiling available in India?
Yes, though access varies. Several accredited laboratories in India offer next-generation sequencing panels, and testing can also be sent to international reference laboratories when needed. Cost and turnaround differ between providers. Ask your oncologist which laboratory they use and what the panel covers, so you know whether it includes the tissue-agnostic markers most relevant to cancer of unknown primary.
What happens if a targeted treatment stops working?
Tumours can develop resistance over time, sometimes through new mutations. If a treatment that was working stops working, your oncologist may recommend a repeat biopsy and fresh molecular profiling to look for what has changed. This is not always the next step, but it is a conversation worth having when your situation changes, because a new profile can sometimes open different treatment options.
Should we get a second opinion before starting treatment?
A second opinion on the molecular profiling results and treatment plan is reasonable, and most oncologists expect it. It is especially useful when no actionable mutation is found, when the tissue-of-origin result is ambiguous, or when the recommended regimen differs from what you have read about. Bring the full pathology report and the genomic profiling result to any second-opinion consultation.